CONSULTATION REPORT:
WHO Report scientific approach pandemic preparedness
Scientific opportunities to achieve fast and equitable access to high-quality and trusted vaccines for future pandemics.
Background
Since 2015, the WHO has implemented a comprehensive global research strategy and preparedness plan known as the WHO R&D Blueprint for Epidemics. A centerpiece of this work is the WHO pathogen priority list which ensures research efforts are concentrated on diseases with epidemic or pandemic potential where medical countermeasures and limited or non-existent. Since November 2022, a new approach has been implemented, focusing on entire classes of viruses or bacteria rather than individual pathogens. Around 200+ scientists from 53 countries are independently evaluating the evidence related to 30 viral families, one core group of bacteria, and “Pathogen X” – an unknown pathogen with the potential to trigger a severe global epidemic. This new approach will also help identify representative viruses (or prototypes) within a viral family as a pathfinder in generating evidence and filling knowledge gaps that may then apply to other viruses of threat in the same family1.
Improved pandemic preparedness could be achieved by proactively managing emerging virus threats focused on four discreet activities using currently available tools:
- discovery and surveillance,
- targeted basic research,
- translational research and product development, and
- clinical trial infrastructure and deployment capacity.
Many have proposed a variety of approaches including promoting basic research, translational research, coordination of access to data, and development of prototype vaccines among others. Coordinating and accelerating global research must promote universal values. Regarding a collaborative effort to ensure access to MCMs during pandemics, some have emphasized the importance of speed and sometimes cost in responding to future pandemics. It is equally important to take a broader view that recognizes the primary importance of quality, equity in access, and trust in the products' safety and efficacy. As a community, we need to explore the different scientific challenges openly and broadly, discuss the scientific solutions being proposed; outline the various potential actions and what problem(s) each action will address2. A series of four consultations have been planned to discuss these matters.
- discovery and surveillance,
- To review the state of the art and the scientific opportunities and challenges
- To outline cross-cutting scientific actions are needed (globally and at the country level) to address the development challenges.
- To discuss and clarify the utility of establishing generalizable research approaches relative to specific product development within viral families.
Many have proposed a variety of approaches including promoting basic research, translational research, coordination of access to data, and development of prototype vaccines among others. Coordinating and accelerating global research must promote universal values. Regarding a collaborative effort to ensure access to MCMs during pandemics, some have emphasized the importance of speed and sometimes cost in responding to future pandemics. It is equally important to take a broader view that recognizes the primary importance of quality, equity in access, and trust in the products' safety and efficacy. As a community, we need to explore the different scientific challenges openly and broadly, discuss the scientific solutions being proposed; outline the various potential actions and what problem(s) each action will address . A series of four consultations have been planned to discuss these matters.
First consultation – 9 January 2024 A Scientific Framework for Epidemics and Pandemics Preparedness |
Second consultation – 18 January 2024 Critical research for priority pathogens with epidemic potential |
Third consultation – 19 January 2024 Research response to pathogen X during a pandemic |
Fourth consultation – February, 2024 Addressing uncertainty during epidemics and pandemics by generating randomized evidence |
Disclaimer - During these meetings, we will not discuss specific national or international initiatives or define or discuss the elements of global governance
---------------------------------------
PRESENTATIONS
Introduction
Summary of previous meeting conclusions
How could vaccine research for a prototype pathogen inform vaccine development for related pathogens?
USING AN IN-DEPTH KNOWLEDGE OF PROTOTYPE VIRAL PATHOGENS WITHIN EACH FAMILY OR GENUS TO INFORM THE DEVELOPMENT OF VACCINES FOR OTHER CLOSELY RELATED FAMILY MEMBERS
FILOVIRUSES
Nancy Sullivan presentation
Robert Cross presentation
HENIPAVIRUS (PARAMYXOVIRUS)
Michael Holbrook presentation
Hector Aguilar presentation
BUNYAVIRUS-ARENAVIRUS
Kathryn Hastie presentation
Lisa Oestereich presentation
ALPHAVIRUS (TOGAVIRUS)
Kenneth Lundstrom presentation
Naomi Forrrester-Soto presentation
Prioritization of candidate products with generalizability in mind
Immune response understanding for specific viral or bacterial family causing the outbreak
WHAT CAN WE LEARN FROM ONGOING AND PAST EXPERIENCES
Broadly protective vaccines for Flu and COVID: where are we and where should we go?
A successful platform experience – History of an Ebola vaccine
Be aware the next pandemic pathogen can be very different: Experience of H5N1
WHO Report scientific approach pandemic preparedness